# Biosafety for Viral Gene Therapies

#### Erich Bozenhardt, PE

## Process Manage


### Abstract

With a maturing pipeline of Gene Therapies, companies are developing commercial manufacturing spaces at a rapid rate. The novel processes/organisms are challenging companies to develop a look at their Biosafety operational practices, how those practices and GMP compliance influence the design of facilities. This poster will help build an understanding of how to classify vectors/cell lines, how risk groups translate into facility design, and what GMP practices around containment need to be considered for viral gene therapies.

## Identify / Assess

US NIH/CDC Risk Group 1

- Not known to cause disease in healthy humans
- Minimal potential hazard to personnel and the environment
- Most Adeno Associated Virus (AAV)
- E. coli, Saccharomyces cerevisiae, SF9



#### US NIH/CDC Risk Group 2

- Agents associated with human diseases, but rarely serious
- Preventative or therapeutic interventions are often available
- Moderate potential hazard to humans and environment
- Adenovirus (AV), AAV w/ helper virus, Lentivirus
- All primary human cells, Most human culture cell lines (e.g. HeLa), SV40 or AV modified cell lines (e.g. HEK-293)

#### Agent classification varies according to national regulation

## Operator/Er

#### **General Practice**

- BSL level need numerical leve
- This protects t
- Each layer mus

#### **Primary Contain**

- **Closed System**
- Aseptic coni
- Tube welding
- Consider dis
- Functionally C
- Closure before
- Sanitize pos
- Open Systems
  - Biological Sa
  - Sanitize mat

#### Secondary Cont

- Hand wash sir
- Self closing do
- Appropriate Pe airborne agen
- Approved met
- Autoclave in
- Closed drain
- Chemical (ve
- Off-site Inac
- Movement of contaminated materials in appropriate containers

ger   IPS – Integrated Project Services LLC	ebozenhardt@ipsdb.com
Environment	Product
eds to add one level of separation for each vel of the BSL designation the operators, the product and the environment ust be an envelope of containment nment (Equipment)	<ul> <li>GMP Segregation</li> <li>Virus / Virus free within train</li> <li>Between products in a facility <ul> <li>Spatial</li> <li>Air flow</li> <li>Procedural / Personnel</li> </ul> </li> </ul>
ms	
nnectors ng lisassembly by tube sealing Closed Systems fore charging virus ost use ns Safety Cabinets aterials and gloves as leaving	<ul> <li>Facility Considerations</li> <li>More but smaller air handlers</li> <li>Inward air flow to contain (bubble/sink airlocks)</li> <li>Air can be recirculated via HEPA</li> <li>Fumigation of suite <ul> <li>Between products</li> <li>Before the boundary is breached for maintenance</li> </ul> </li> <li>Maximize the use of unidirectional flow <ul> <li>Time segregation for infrequent movements</li> </ul> </li> </ul>
itainment (Facility)	
ink at exit doors	Conclusion
Personal Protective Equipment (e.g. masks for nts) ethod of decontaminated waste in building in system w/ inactivation system for larger scale verify local expectations) activation (verify local expectations)	<ul> <li>Review local regulations.</li> <li>Carefully consider the containment boundaries.</li> <li>Maximize closed processing.</li> <li>Develop robust waste handling practices.</li> <li>Segregate and plan for fumigation within the suite boundaries.</li> </ul>

- Waste in sealed bag moved on cart with spill containment



g practices. ation within the suite boundary.